Abstract
Stroke is the leading cause of disability and the second leading cause of death worldwide. Diabetes mellitus is an important independent cardiovascular risk factor in patients, regardless of age, smoking habit, and hypertension. Approximately one-third of first-time ischemic stroke patients have diabetes. Inflammation is among the most important pathological mechanisms in atheroma formation, the damage cascades of the acute phase, as well as during the subacute and chronic phases after stroke. Diabetes, as a common risk factor for stroke, is often present for a long time before a stroke occurs, causing low-grade inflammation, and disrupting the proper functioning of the neurovascular units. These proinflammatory processes and maladaptive immune mechanisms are further accelerated after cerebral ischemia and worsen the stroke outcome in diabetic patients. Clinical treatments for ischemic stroke are currently focused on restoring cerebral blood flow (reperfusion) in the acute phase, including thrombolysis and mechanical thrombectomy, which are not applicable to patients that fall outside of the treatment window and/or without large-vessel occlusion. There are few approved treatments targeting cellular injury caused by inflammation. There are even fewer data on effective treatment for diabetic stroke targeting inflammation. This paper presents the second part of a review focusing on the potential therapeutic targets in stroke patients with type 2 diabetes.
| Original language | English |
|---|---|
| Article number | 1694 |
| Journal | Advanced Neurology |
| Volume | 3 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2024 |
Keywords
- Diabetes
- Inflammation
- Pathophysiology
- Stroke
- Therapeutic
